Gastroenterology

Gastroenterology

Volume 131, Issue 6, December 2006, Pages 1981-2002
Gastroenterology

AGA Institute
American Gastroenterological Association (AGA) Institute Technical Review on the Diagnosis and Management of Celiac Disease

https://doi.org/10.1053/j.gastro.2006.10.004Get rights and content

This technical review addresses the state of evidence for celiac disease epidemiology, detection by serologic testing, diagnosis by biopsy, treatment, and outcome. It updates the previous American Gastroenterological Association (AGA) Institute technical review on celiac disease published in 2001.

Section snippets

Pathology

Although celiac disease has consequences for many organs, the site of maximum impact is the proximal small intestine, which is where dietary gluten first encounters the mucosal immune system. Over the past 50 years, celiac disease has become defined by this small intestinal damage. Our understanding of the spectrum of injury and its consequences has increased substantially over the past several years. There are varying degrees of inflammation and architectural changes that occur at presentation

Pathogenesis

Recent information has illuminated our understanding of the basic mechanisms that lead to the development of celiac disease. We briefly summarize these advances to provide a pathophysiologic context for the more detailed analysis of questions of immediate importance to clinical practice. Furthermore, such pathophysiologic insights into the disease suggest potential therapeutic alternatives that ultimately may be substitutes or adjuncts to the GFD. A full review of the processes that lead to the

Aim of the Technical Review

The aim of this technical review on celiac disease is to address specific areas of clinical importance relevant to practicing gastroenterologists and primary care practitioners who see and detect most cases of celiac disease. The major focus is on adults, although some data from studies on children are also included for completeness. The specific issues related to celiac disease in childhood have been recently addressed.11

Methods

This technical review was conducted using standard systematic review methodology to address several key content areas regarding celiac disease: use of serologic testing in diagnosis, use of HLA-DQ2/DQ8 testing in diagnosis, prevalence of celiac disease in the general population and in groups of individuals presumed to be at increased risk for celiac disease, complications of celiac disease, benefits of a GFD, promoting adherence to a GFD, and maintaining adherence to a GFD. The specific

Diagnosis of Celiac Disease

The diagnostic approach to detecting celiac disease has undergone important changes in recent years. This reflects the development and application of serologic tests, particularly the EMA and tTG antibody tests, as an initial screen for this disease. Serologic tests are largely responsible for the recognition that celiac disease is not a rare disease. Moreover, with the recognition of a relatively high prevalence of celiac disease in the US population (∼1:100) has come increased recognition of

Epidemiology

Celiac disease has been classified into 4 phenotypes,30 as described in Table 3. “Classic” celiac disease is dominated by the symptoms and sequelae of gastrointestinal malabsorption. “Atypical” celiac disease is characterized by few or no gastrointestinal symptoms, with extraintestinal manifestations predominating.30 Of note, atypical celiac disease is more prevalent than classic celiac disease, which could call into question the use of these terms. “Silent” celiac disease is used when

Prevalence of Celiac Disease in the General Population

Much of the data on the prevalence of celiac disease in the general population has come from western European countries, where celiac disease previously was believed to be more common than in other parts of the world, including the United States. However, it is now apparent that celiac disease is also common in the United States, Eastern Europe, and many other countries with the exception of Japan.31, 32, 33, 34

The prevalence of celiac disease varies greatly across and within different

Mortality

Mortality associated with celiac disease has been assessed in several cohort studies230, 231, 232, 233, 234, 235 and a survey. Among the cohort studies, included patients had biopsy-proven celiac disease, and the majority had symptomatic celiac disease. The death rate in patients with celiac disease was higher than that of a standardized population rate or of a control population in all but one study.236 In the remaining studies, the standardized mortality rate (SMR; the ratio of the number of

Protection From NHL

Compliance with a GFD is likely protective against NHL in patients with celiac disease. Holmes et al reported a significant risk reduction of NHL in patients on a strict GFD (SIR, 44.4) versus those who did not adhere to a GFD (SIR, 100).246 Others reported that a cohort of 383 patients with celiac disease with a very high prevalence of strict adherence to a GFD did not have a significantly increased risk of NHL compared with the general population (SIR, 2.66; 95% CI, 0.07–14.8).242 Also, a

Promoting Adherence to a GFD

The treatment of celiac disease is lifelong adherence to a GFD. The preceding sections have discussed the benefits of identifying and treating patients with celiac disease. However, changes in dietary habits are difficult to maintain, and there are many barriers to continued compliance with a GFD. Adding to the difficulty of assessing any proposed intervention is the lack of certainty as to how best to measure compliance with a GFD.

Existing evidence suggests a positive correlation between

Monitoring Adherence to a GFD

Patients with celiac disease should be evaluated at regular intervals by a health care team including a physician and a dietician. These visits can be used to assess, by history, a patient’s compliance with a GFD and to reinforce the importance of such compliance. Beyond this, there are no clear guidelines as to the optimal means to monitor adherence to a GFD. Symptom improvement alone may not offer an accurate assessment of adherence to a GFD as judged by interview or by biopsy,278 and this

Continued or Relapsing Symptoms in Treated Celiac Disease

Patients with known celiac disease can continue to have or redevelop symptoms despite being on a GFD. It is important to review the original diagnosis to ensure that it is accurate, and a repeat small intestinal biopsy may be indicated in patients with a poor response to a GFD. These symptoms may be due to incompletely healed celiac disease, an associated condition, a complication, or a second unrelated diagnosis.297 Persistent or intermittent symptoms due to deliberate or inadvertent ingestion

References (303)

  • C.G.D.S. Csizmadia et al.

    An iceberg of childhood coeliac disease in the Netherlands

    Lancet

    (1999)
  • C. Catassi et al.

    Coeliac disease in the year 2000: exploring the iceberg

    Lancet

    (1994)
  • E. Fabiani et al.

    Anti-human versus anti-guinea pig tissue transglutaminase antibodies as the first-level serological screening test for coeliac disease in the general population

    Dig Liver Dis

    (2004)
  • G. Corazza et al.

    Gliadin immune reactivity is associated with overt and latent enteropathy in relatives of celiac patients

    Gastroenterology

    (1992)
  • L. Book et al.

    Prevalence of celiac disease among relatives of sib pairs with celiac disease in U.S. families

    Am J Gastroenterol

    (2003)
  • I. Hill et al.

    The prevalence of celiac disease in at-risk groups of children in the United States

    J Pediatr

    (2000)
  • B. Annibale et al.

    Gastrointestinal causes of refractory iron deficiency anemia in patients without gastrointestinal symptoms

    Am J Med

    (2001)
  • K. Kaukinen et al.

    Celiac disease without villous atrophy: revision of criteria called for

    Dig Dis Sci

    (2001)
  • K. Kaukinen et al.

    Small-bowel mucosal inflammation in reticulin or gliadin antibody-positive patients without villous atrophy

    Scand J Gastroenterol

    (1998)
  • T. Reunala

    Dermatitis herpetiformis: coeliac disease of the skin

    Ann Med

    (1998)
  • L. Shan et al.

    Structural basis for gluten intolerance in celiac sprue

    Science

    (2002)
  • I.D. Hill et al.

    Guideline for the diagnosis and treatment of celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition

    J Pediatr Gastroenterol Nutr

    (2005)
  • A. Rostom et al.

    Celiac disease

    Evid Rep Technol Assess (Summ)

    (2004)
  • A.S. McNeish et al.

    The diagnosis of coeliac diseaseA commentary on the current practices of members of the European Society for Paediatric Gastroenterology and Nutrition (ESPGAN)

    Arch Dis Child

    (1979)
  • J.A. Walker-Smith et al.

    Revised criteria for diagnosis of coeliac disease

    Arch Dis Child

    (1990)
  • N. Leonard et al.

    Peptic duodenitis—does it exist in the second part of the duodenum?

    J Clin Pathol

    (1997)
  • N. Ansaldi et al.

    Clinico-histological behavior of celiac patients after gluten load following the definitive diagnosis

    Pediatr Med Chir

    (1988)
  • P. Collin et al.

    Antiendomysial and antihuman recombinant tissue transglutaminase antibodies in the diagnosis of coeliac disease: a biopsy-proven European multicentre study

    Eur J Gastroenterol Hepatol

    (2005)
  • F. Cataldo et al.

    Prevalence and clinical features of selective immunoglobulin A deficiency in coeliac disease: an Italian multicentre study

    Gut

    (1998)
  • M.A. Heneghan et al.

    Celiac sprue and immunodeficiency states: a 25-year review

    J Clin Gastroenterol

    (1997)
  • V. Kumar et al.

    Celiac disease and immunoglobulin a deficiency: how effective are the serological methods of diagnosis?

    Clin Diagn Lab Immunol

    (2002)
  • P. Collin et al.

    Selective IgA deficiency and coeliac disease

    Scand J Gastroenterol

    (1992)
  • F. Cataldo et al.

    IgG(1) antiendomysium and IgG antitissue transglutaminase (anti-tTG) antibodies in coeliac patients with selective IgA deficiencyWorking Groups on Celiac Disease of SIGEP and Club del Tenue

    Gut

    (2000)
  • I.R. Korponay-Szabo et al.

    Elevation of IgG antibodies against tissue transglutaminase as a diagnostic tool for coeliac disease in selective IgA deficiency

    Gut

    (2003)
  • W. Vader et al.

    The HLA-DQ2 gene dose effect in celiac disease is directly related to the magnitude and breadth of gluten-specific T cell responses

    Proc Natl Acad Sci U S A

    (2003)
  • A. Doolan et al.

    Use of HLA typing in diagnosing celiac disease in patients with type 1 diabetes

    Diabetes Care

    (2005)
  • National Institutes of Health Consensus Development Conference Statement on Celiac Disease, June 28-30, 2004

    Gastroenterology

    (2005)
  • C. Catassi et al.

    The distribution of DQ genes in the Saharawi population provides only a partial explanation for the high celiac disease prevalence

    Tissue Antigens

    (2001)
  • U. Poddar et al.

    Celiac disease in India: are they true cases of celiac disease?

    J Pediatr Gastroenterol Nutr

    (2002)
  • R. Elsurer et al.

    Celiac disease in the Turkish population

    Dig Dis Sci

    (2005)
  • S. Gursoy et al.

    The prevalence of unrecognized adult celiac disease in Central Anatolia

    J Clin Gastroenterol

    (2005)
  • E. Grodzinsky et al.

    Presence of IgA and IgG antigliadin antibodies in healthy adults as measured by micro-ELISAEffect of various cutoff levels on specificity and sensitivity when diagnosing coeliac disease

    Int Arch Allergy Appl Immunol

    (1990)
  • A.K. Carlsson et al.

    Serological screening for celiac disease in healthy 2.5-year-old children in Sweden

    Pediatrics

    (2001)
  • P. Collin et al.

    The hunt for coeliac disease in primary care

    Q J Med

    (2002)
  • E. Grodzinsky

    Screening for coeliac disease in apparently healthy blood donors

    Acta Paediatr

    (1996)
  • E. Grodzinsky et al.

    High prevalence of celiac disease in healthy adults revealed by antigliadin antibodies

    Ann Allergy

    (1992)
  • N. Hovdenak et al.

    High prevalence of asymptomatic coeliac disease in Norway: a study of blood donors

    Eur J Gastroenterol Hepatol

    (1999)
  • A. Ivarsson et al.

    High prevalence of undiagnosed coeliac disease in adults: a Swedish population-based study

    J Intern Med

    (1999)
  • C. Lagerqvist et al.

    Screening for adult coeliac disease - which serological marker(s) to use?

    J Intern Med

    (2001)
  • K.L. Kolho et al.

    Undiagnosed coeliac disease is common in Finnish adults

    Scand J Gastroenterol

    (1998)
  • Cited by (631)

    View all citing articles on Scopus

    This literature review and the recommendations therein were prepared for the AGA Institute Clinical Practice and Economics Committee. The paper was approved by the Committee on August 21, 2006, and by the AGA Institute Governing Board on September 25, 2006.

    1

    M.F.K. is supported by National Institutes of Health grants DK35108 and DK58960 and a grant from the William K. Warren Foundation, and J.A.M. is supported by National Institutes of Health grants DK 71003 and DK 57892.

    View full text